EXO<sup>TLR1/2-STING</sup>: A Dual-Mechanism Stimulator of Interferon Genes Activator for Cancer Immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39846950.
- Also identified by DOI 10.1021/acsnano.4c18056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As natural agonists of the stimulator of interferon genes (STING) protein, cyclic dinucleotides (CDNs) can activate the STING pathway, leading to the expression of type I interferons and various cytokines. Efficient activation of the STING pathway in antigen-presenting cells (APCs) and tumor cells is crucial for antitumor immune response. Tumor-derived exosomes can be effectively internalized by APCs and tumor cells and have excellent potential to deliver CDNs to the cytoplasm of APCs and tumor cells. Here, we leverage tumor exosomes as a delivery platform, designing an EXO<sup>TLR1/2-STING</sup> loaded with CDNs. To achieve efficient loading of CDNs onto exosomes, we chemically conjugated CDNs with Pam<sub>3</sub>CSK<sub>4</sub>, a compound featuring multiple fatty acid chains, resulting in Pam<sub>3</sub>CSK<sub>4</sub>-CDG<sup>SF</sup>. Utilizing the high lipophilicity of Pam<sub>3</sub>CSK<sub>4</sub>, Pam<sub>3</sub>CSK<sub>4</sub>-CDG<sup>SF</sup> could be efficiently loaded onto the exosomes through simple incubation. Moreover, as an agonist for Toll-like receptor 1/2, Pam<sub>3</sub>CSK<sub>4</sub> also exhibits robust immunological synergistic effects in conjunction with CDNs. EXO<sup>TLR1/2-STING</sup> effectively induced the activation of APCs and triggered tumor cell death, producing a favorable antitumor therapeutic effect. It also demonstrated significant synergistic effects with immune checkpoint therapies.
Medical subject headings
- Immunotherapy
- Membrane Proteins
- Neoplasms